Bibliography
- Murphy PM, Charo IF, Hills R, Chemokine receptors, introductory chapter. IUPHAR database (IUPHAR-DB). Available from: http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId = 14 [Last modified on 13 October 2009, Accessed on 05 September 2011]
- Pease JE, Horuk R. Chemokine receptor antagonists: part 1. Expert Opin Ther Pat 2009;19(1):39-5
- Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 2009;19(2):199-221
- Pease JE, Horuk R. Small molecule antagonists of chemokine receptors–is promiscuity a virtue? Curr Top Med Chem 2010;10(13):1351-8
- Hall SE, Mao A, Nicolaidou V, Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 2009;75(6):1325-36
- Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 2010;88(1):41-55
- Pasternak A, Goble SD, Struthers M, Discovery of a potent and orally bioavailable CCR2 and CCR5 dual antagonist. ACS Med Chem Lett 2010;1(1):14-18
- Singh JP, Yu X, Wang G, A potent anti-inflammatory CCR2/CCR5 dual antagonist abrogates adipose inflammation and glucose intolerance, and reduces fat mass in a preclinical model of diet induced obesity. Circulation 2008;118(S_503):abstract 3922
- Zhao Q, Pang J, McIntyre K, A CCR2/CCR5-dual antagonist, BMS-A, offers a potential novel oral therapy for the treatment of autoimmune disease. J Immunol 2009;182:92-6
- Miltz W, Loetscher P, Janser P, Dual CCR2/CCR5 antagonists: a new approach for the treatment of autoimmune diseases. The 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008. MEDI 163. Available from: http://oasys2.confex.com/acs/235nm/techprogram/P1158061.HTM
- Padi SSV, Shi XQ, Zhao YZ, Prevention and reversal of rodent neuropathic pain by a CCR2/CCR5 dual antagonist, RAP103. Available from: http://www.rapidpharma.com/uploads/media/2010-03_Poster.pdf
- Marier JF, Trinh M, Pheng LH, Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob Agents Chemother 2011;55(6):2768-74
- Zheng C, Cao G, Xia M, Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist. Bioorg Med Chem Lett 2011;21(5):1442-6
- NCT01049165 Single Ascending Dose (BMS-813160) Study. Available from: http://clinicaltrials.gov/ct2/show/NCT01049165?term=NCT01049165&rank=1
- Bristol-Myers Squibb. Modulators of chemokine receptor activity, crystalline forms and process. WO2008014381; 2008
- Bristol-Myers Squibb. Cyclic derivatives as modulators of chemokine receptor activity. WO2005021500; 2005
- Bristol-Myers Squibb. Modulators of chemokine receptor activity, crystalline forms and process. WO2008014360; 2008
- Bristol-Myers Squibb. Cyclic derivatives as modulators of chemokine receptor activity. US7163937; 2007
- Baba M, Takashima K, Miyake H, TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 2005;49(11):4584-91